Characterizing rare soft tissue sarcomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project involves a comprehensive clinical and biological characterization of rare subtypes of soft tissue sarcomas through a prospective cohort of 400 patients and a retrospective analysis of 100 cases. Patients will be identified from various centers either during routine care or through clinical study protocols. The study aims to gather detailed information on these rare sarcoma subtypes to improve understanding and treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years at the time of study entry.
2. Diagnosis of one of the following rare sarcoma subtype, confirmed by RRePS network:

   * Clear Cell Sarcoma (CCS)
   * Epithelioid Sarcoma (ES)
   * Perivascular Epithelioid Cell neoplasm (PEComa)
   * Desmoplastic Small Round Cell Tumours (DSRCT)
   * Malignant Solitary Fibrous Tumours (mSFT)
   * Alveolar Soft Part Sarcoma (ASPS)
   * Epithelioid Hemangioendothelioma (EH)
   * Low-Grade Fibromyxoid Sarcoma (LGFS)
   * Sclerosing Epithelioid Fibrosarcoma (SEF).
3. Localized/locally advanced or metastatic disease.
4. In case of localized disease, treatment must not have been yet initiated before inclusion (except surgical excision).
5. In case of metastatic disease, project of new line of systemic treatment must have been decided before inclusion.
6. Patient followed in the center within a standard of care procedure or clinical trial.
7. Archived tumor specimen at initial diagnosis available (before treatment initiation).
8. Evaluable disease (measurable as per RECIST 1.1) or not.
9. ECOG Performance status 0-3.
10. Patient able to participate and willing to give informed consent prior to performance of any study-related procedures.
11. Patient affiliated to a Social Health Insurance in France.

Exclusion Criteria:

1. Diagnosis of all other histotypes of soft tissue sarcoma.
2. Any condition contraindicated with procedures required by the protocol.
3. Known history of positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
5. Pregnant or breast-feeding woman.
6. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Where it's running

• Chu Besancon - Site Jean Minjoz
  Besançon, France Recruiting
• Institut Bergonié
  Bordeaux, France Recruiting
• Centre Jean Perrin
  Clermont-Ferrand, France Recruiting
• Centre Oscar Lambret
  Lille, France Recruiting
• Chu Dupuytren
  Limoges, France Recruiting
• Centre Leon Berard
  Lyon, France Recruiting

Study contacts

• Study coordinator: Thibaud VALENTIN
• Email: Valentin.Thibaud@iuct-oncopole.fr
• Phone: +33 (0)5 31 15 51 70

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating treatments for non-rhabdomyosarcoma soft tissue sarcoma in young patients

  This study is testing a combination of chemotherapy and radiation to see if it helps young patients with non-rhabdomyosarcoma soft tissue sarcoma live longer without their cancer coming back.

  Recruiting at 7 sites Phase 1/2 St. Jude Children's Research Hospital · Atlanta, Georgia and 6 other locations · NCT06239272

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• B7-H3 CAR T-cell therapy for pediatric solid tumors

  This study is testing a new type of immune therapy using specially modified T cells to see if it can help children with tough-to-treat solid tumors.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04897321

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

• Phase 3 test of anlotinib (AL3818) versus dacarbazine in advanced alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma

  This trial tests whether anlotinib (AL3818) helps adults with advanced alveolar soft part sarcoma, while earlier arms compared anlotinib to dacarbazine for leiomyosarcoma and synovial sarcoma that are no longer enrolling.

  Recruiting Phase 3 Advenchen Laboratories, LLC · Phoenix, Arizona and 23 other locations · NCT03016819

• 68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients

  This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.

  Recruiting Phase 2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd · Wuhan, Hubei · NCT07920835

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.